secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001323885-24-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28
------------------------------------------------------------------

- Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
- GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).
- Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.
- Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.
- CEO cites strong start with growth across all franchises; new product launches and clinical research ahead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/0001323885-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/atrc-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001323885-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer